2 news items
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
REGN
16 Jun 24
those with high cytogenetic risk, 45% (9 of 20 patients) among Black or African American patients, and 28% (10 of 36 patients) among those
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
REGN
7 Apr 24
% among Black or African American patients (17 of 20 patients)71% among those aged 75 years or older (22 of 31 patients)67% among those
- Prev
- 1
- Next